Research graph
References from Development of a combined GMMA and glycoconjugate iNTS-TCV trivalent vaccine against invasive salmonellosis. Local targets link to admitted publications; unresolved targets remain external evidence.
The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s1473-3099(18)30685-6 · 2019 · External reference
D. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s1473-3099(19)30418-9 · 2019 · External reference
The global, regional, and national burden of Invasive Non-typhoidal Salmonella (iNTS): An analysis from the Global Burden of Disease Study 1990–2021
10.1371/journal.pntd.0012960 · 2025 · External reference
S. c. c. Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis
10.1016/s1473-3099(21)00615-0 · 2022 · External reference
Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa
10.1016/s0140-6736(11)61752-2 · 2012 · External reference
A genomic appraisal of invasive Salmonella Typhimurium and associated antibiotic resistance in sub-Saharan Africa
10.1038/s41467-023-41152-6 · 2023 · External reference
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation
10.1016/j.vaccine.2025.127008 · 2025 · External reference
The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead
10.1016/j.vaccine.2026.128339 · 2026 · External reference
The global burden of typhoid and paratyphoid fever from 1990 to 2021 and the impact on prevention and control
10.1186/s12879-025-11223-8 · 2025 · External reference
The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s1473-3099(18)30685-6 · 2019 · External reference
10.1016/j.vaccine.2018.04.022
10.1016/j.vaccine.2018.04.022 · 2019 · External reference
Salmonella Combination Vaccines: Moving Beyond Typhoid
10.1093/ofid/ofad041 · 2023 · External reference
Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations
10.1016/j.vaccine.2025.127515 · 2025 · External reference
High yield production process for Shigella outer membrane particles
10.1371/journal.pone.0035616 · 2012 · External reference
Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis
10.1128/cvi.00023-16 · 2016 · External reference
Development of a GMMA-based candidate vaccine against invasive nontyphoidal Salmonella disease
10.3389/fimmu.2026.1821495 · 2026 · External reference
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator
10.1080/21645515.2022.2043103 · 2022 · External reference
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
10.1073/pnas.1807655115 · 2018 · External reference
Vacc-i, N. T. S. C. C. Incidence of non-typhoidal Salmonella invasive disease: a systematic review and meta-analysis
10.1016/j.jinf.2021.06.029 · 2021 · External reference
Prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars isolated from normally sterile sites: A global systematic review
10.1017/s0950268823001693 · 2023 · External reference
GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevant Salmonellae
10.3389/fimmu.2025.1610067 · 2025 · External reference
GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype 6
10.3390/vaccines8020160 · 2020 · External reference
10.1016/j.ebiom.2017.07.013
10.1016/j.ebiom.2017.07.013 · 2017 · External reference
Vaccines for preventing typhoid fever
10.1002/14651858.cd001261.pub2 · 2007 · External reference
Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi
10.1128/cvi.00387-10 · 2011 · External reference
Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM(197) conjugate vaccine
10.1073/pnas.2005857117 · 2020 · External reference
Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults
10.1371/journal.pone.0025398 · 2011 · External reference
Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi
10.1016/j.vaccine.2010.11.022 · 2011 · External reference
Characterization of the Salmonella paratyphi C Vi polysaccharide
10.1128/iai.57.10.3159-3164.1989 · 1989 · External reference
Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis
10.1016/j.vaccine.2006.03.002 · 2006 · External reference
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever; ClinicalTrials.gov ID NCT05480800; Protocol Number: 216152 (INTS-GMMA GVGH-002) (H08_01TP)
External reference
Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial
10.1016/j.ebiom.2025.105903 · 2025 · External reference
o. PACTR202310834458532; Phase 1 Clinical Study to Evaluate the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoidal Salmonella in healthy Kenyan adults
External reference
Unresolved reference
External reference
Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB
10.1371/journal.pone.0134478 · 2015 · External reference
Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi
10.1016/j.vaccine.2011.11.108 · 2012 · External reference
Development of a Specific and Sensitive HPAEC-PAD Method for Quantification of Vi Polysaccharide Applicable to other Polysaccharides Containing Amino Uronic Acids
10.1021/acs.analchem.9b05107 · 2020 · External reference
Gram-Negative Bacteria's Outer Membrane Vesicles
10.3947/ic.2022.0145 · 2023 · External reference
Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6
1995 · External reference
Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate Formulation
10.3390/molecules23071749 · 2018 · External reference
Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to
10.1093/infdis/jiag156 · 2026 · External reference
[A newly discovered chemotactic factor for neutrophil: interleukin 8]
1992 · External reference
ROS/TNF-alpha Crosstalk Triggers the Expression of IL-8 and MCP-1 in Human Monocytic THP-1 Cells via the NF-kappaB and ERK1/2 Mediated Signaling
10.3390/ijms221910519 · 2021 · External reference
Monocyte chemoattractant protein-1 (MCP-1): an overview
10.1089/jir.2008.0027 · 2009 · External reference
Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis
10.1086/314559 · 1999 · External reference
Adoptive transfer of immunity to oral challenge with virulent salmonellae in innately susceptible BALB/c mice requires both immune serum and T cells
10.1128/iai.61.9.3981-3984.1993 · 1993 · External reference
Modelling within-host spatiotemporal dynamics of invasive bacterial disease
10.1371/journal.pbio.0060074 · 2008 · External reference
Human IgG isotypes and activating Fcgamma receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells
10.1111/j.1365-2567.2011.03411.x · 2011 · External reference
Testing S. sonnei GMMA with and without Aluminium Salt-Based Adjuvants in Animal Models
10.3390/pharmaceutics16040568 · 2024 · External reference
Development of a Monocyte Activation Test as an Alternative to the Rabbit Pyrogen Test for Mono- and Multi-Component Shigella GMMA-Based Vaccines
10.3390/microorganisms9071375 · 2021 · External reference
Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans
10.1080/21645515.2020.1780092 · 2021 · External reference
Reference collection of strains of the Salmonella typhimurium complex from natural populations
10.1099/00221287-137-3-601 · 1991 · External reference
Strain Selection for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive Nontyphoidal Salmonella Disease
10.1371/journal.pone.0139847 · 2015 · External reference
Pan-European resistance monitoring programmes encompassing food-borne bacteria and target pathogens of food-producing and companion animals
10.1016/j.ijantimicag.2012.11.004 · 2013 · External reference
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
10.1073/pnas.120163297 · 2000 · External reference
Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants
10.1074/jbc.m114.566570 · 2014 · External reference
A next-generation GMMA-based vaccine candidate to fight shigellosis
10.1038/s41541-023-00725-8 · 2023 · External reference
Methods for Assessment of OMV/GMMA Quality and Stability
10.1007/978-1-0716-1900-1_14 · 2022 · External reference
Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach
10.1016/j.jim.2019.04.012 · 2019 · External reference
Unresolved reference
External reference
Characterization of Enzyme-Linked Immunosorbent Assay (ELISA) for Quantification of Antibodies against Salmonella Typhimurium and Salmonella Enteritidis O-Antigens in Human Sera
10.3390/biotech12030054 · 2023 · External reference
Qualification of an enzyme-linked immunosorbent assay for quantification of anti-Vi IgG in human sera
10.3389/fimmu.2024.1466869 · 2024 · External reference
Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout
10.1371/journal.pone.0172163 · 2017 · External reference
Development and Characterization of a Luminescence-Based High-Throughput Serum Bactericidal Assay (L-SBA) to Assess Bactericidal Activity of Human Sera against Nontyphoidal Salmonella
10.3390/mps5060100 · 2022 · External reference
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype
10.1101/gr.091017.109 · 2009 · External reference
A scalable method for O-antigen purification applied to various Salmonella serovars
10.1016/j.ab.2012.10.038 · 2013 · External reference
